• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PDL1: The Illusion of an Ideal Biomarker.

作者信息

Apolo Andrea B

机构信息

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

出版信息

Eur Urol Focus. 2016 Feb;1(3):269-271. doi: 10.1016/j.euf.2015.04.005. Epub 2015 Jun 6.

DOI:10.1016/j.euf.2015.04.005
PMID:28723398
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6776418/
Abstract
摘要

相似文献

1
PDL1: The Illusion of an Ideal Biomarker.程序性死亡配体1：理想生物标志物的假象
Eur Urol Focus. 2016 Feb;1(3):269-271. doi: 10.1016/j.euf.2015.04.005. Epub 2015 Jun 6.
2
Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy.抗 PD1/PDL1 IgG 亚类分布在十种癌症类型和抗 PD1 IgG4 作为 NSCLC 患者抗 PD1 治疗长期生存的生物标志物。
Cancer Immunol Immunother. 2022 Jul;71(7):1681-1691. doi: 10.1007/s00262-021-03106-z. Epub 2021 Nov 24.
3
The Immune Checkpoint Regulator PDL1 is an Independent Prognostic Biomarker for Biochemical Recurrence in Prostate Cancer Patients Following Adjuvant Hormonal Therapy.免疫检查点调节因子PDL1是前列腺癌患者辅助激素治疗后生化复发的独立预后生物标志物。
J Cancer. 2019 Jun 2;10(14):3102-3111. doi: 10.7150/jca.30384. eCollection 2019.
4
A novel epigenetic biomarker, plasma miR-138-5p gene promoter-methylated DNA, for colorectal cancer diagnosis.一种新型的表观遗传生物标志物，血浆 miR-138-5p 基因启动子甲基化 DNA，用于结直肠癌诊断。
Per Med. 2022 Jul;19(4):315-325. doi: 10.2217/pme-2021-0095. Epub 2022 Jun 17.
5
The B7H4-PDL1 classifier stratifies immuno-phenotype in cervical cancer.B7H4-PDL1分类器可对宫颈癌的免疫表型进行分层。
Cancer Cell Int. 2022 Jan 4;22(1):3. doi: 10.1186/s12935-021-02423-8.
6
Association Between Genetic Variation and Efficacy of Apatinib Monotherapy in Patients with Previously Treated Advanced NSCLC: A Real-World Retrospective Study.既往接受过治疗的晚期非小细胞肺癌患者中阿帕替尼单药治疗的基因变异与疗效之间的关联：一项真实世界回顾性研究
Int J Gen Med. 2021 Jun 21;14:2703-2714. doi: 10.2147/IJGM.S303717. eCollection 2021.
7
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.实体瘤中 PDL1 扩增的流行率和免疫检查点阻断的初步反应。
JAMA Oncol. 2018 Sep 1;4(9):1237-1244. doi: 10.1001/jamaoncol.2018.1701.
8
Phospho‑STAT1 expression as a potential biomarker for anti‑PD‑1/anti‑PD‑L1 immunotherapy for breast cancer.磷酸化 STAT1 表达作为抗 PD-1/抗 PD-L1 免疫治疗乳腺癌的潜在生物标志物。
Int J Oncol. 2019 Jun;54(6):2030-2038. doi: 10.3892/ijo.2019.4779. Epub 2019 Apr 10.
9
Prognostic Value of KRAS Mutations in Relation to PDL1 Expression and Immunotherapy Treatment in Adenocarcinoma and Squamous Cell Carcinoma Patients: A Greek Cohort Study.KRAS突变在腺癌和鳞状细胞癌患者中与PDL1表达及免疫治疗的预后价值：一项希腊队列研究
J Pers Med. 2024 Apr 25;14(5):457. doi: 10.3390/jpm14050457.
10
The importance of exosomal PDL1 in tumour immune evasion.外泌体 PD-L1 在肿瘤免疫逃逸中的重要性。
Nat Rev Immunol. 2020 Apr;20(4):209-215. doi: 10.1038/s41577-019-0264-y. Epub 2020 Jan 21.

引用本文的文献

1
Landscape of Immunotherapy in Genitourinary Malignancies.泌尿生殖系统恶性肿瘤的免疫治疗全景。
Adv Exp Med Biol. 2021;1342:143-192. doi: 10.1007/978-3-030-79308-1_5.
2
Comprehensive tumor molecular profile analysis in clinical practice.临床实践中的全面肿瘤分子特征分析。
BMC Med Genomics. 2021 Apr 14;14(1):105. doi: 10.1186/s12920-021-00952-9.
3
Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer.循环肿瘤细胞亚型和 T 细胞群体作为转移性泌尿生殖系统癌症患者联合免疫治疗的预后生物标志物。
Clin Cancer Res. 2021 Mar 1;27(5):1391-1398. doi: 10.1158/1078-0432.CCR-20-2891. Epub 2020 Dec 1.
4
Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.抗程序性细胞死亡蛋白 1/配体 1（PD-1/PD-L1）抗体治疗尿路上皮癌：现状与未来发展。
Clin Genitourin Cancer. 2018 Apr;16(2):117-129. doi: 10.1016/j.clgc.2017.11.002. Epub 2017 Dec 6.
5
Immunotherapy: a new treatment paradigm in bladder cancer.免疫疗法：膀胱癌治疗的新范式。
Curr Opin Oncol. 2017 May;29(3):184-195. doi: 10.1097/CCO.0000000000000366.
6
Expression patterns of programmed death-ligand 1 in esophageal adenocarcinomas: comparison between primary tumors and metastases.食管腺癌中程序性死亡配体1的表达模式：原发性肿瘤与转移灶的比较
Cancer Immunol Immunother. 2017 Jun;66(6):777-786. doi: 10.1007/s00262-017-1982-2. Epub 2017 Mar 13.
7
Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.美国国立癌症研究所非肌层浸润性膀胱癌新型疗法临床试验规划会议的总结与建议
Bladder Cancer. 2016 Apr 27;2(2):165-202. doi: 10.3233/BLC-160053.
8
Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches.原发性和转移性阴茎鳞状细胞癌中频繁的程序性死亡受体配体1（PD-L1）表达：免疫治疗方法的潜在机遇
Ann Oncol. 2016 Sep;27(9):1706-12. doi: 10.1093/annonc/mdw216. Epub 2016 May 23.

本文引用的文献

1
Expression of PDL1 (B7-H1) Before and After Neoadjuvant Chemotherapy in Urothelial Carcinoma.尿路上皮癌新辅助化疗前后PDL1（B7-H1）的表达
Eur Urol Focus. 2016 Feb;1(3):265-268. doi: 10.1016/j.euf.2015.03.004. Epub 2015 Jun 6.
2
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.纳武单抗治疗转移性肾细胞癌：一项随机II期试验的结果
J Clin Oncol. 2015 May 1;33(13):1430-7. doi: 10.1200/JCO.2014.59.0703. Epub 2014 Dec 1.
3
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.癌症患者对抗PD-L1抗体MPDL3280A反应的预测性相关因素。
Nature. 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011.
4
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.MPDL3280A（抗 PD-L1）治疗可导致转移性膀胱癌的临床活性。
Nature. 2014 Nov 27;515(7528):558-62. doi: 10.1038/nature13904.
5
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.程序性死亡受体-1（PD-1）、PD-1配体与肿瘤免疫微环境的其他特征与抗PD-1治疗反应的相关性
Clin Cancer Res. 2014 Oct 1;20(19):5064-74. doi: 10.1158/1078-0432.CCR-13-3271. Epub 2014 Apr 8.
6
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.基于免疫的细胞毒化疗机制：对设计新型合理联合治疗癌症的启示。
Cell Death Differ. 2014 Jan;21(1):15-25. doi: 10.1038/cdd.2013.67. Epub 2013 Jun 21.
7
Nivolumab plus ipilimumab in advanced melanoma.纳武利尤单抗联合伊匹单抗治疗晚期黑色素瘤。
N Engl J Med. 2013 Jul 11;369(2):122-33. doi: 10.1056/NEJMoa1302369. Epub 2013 Jun 2.
8
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.抗 PD-L1 抗体在晚期癌症患者中的安全性和活性。
N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2.
9
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.抗 PD-1 抗体在癌症中的安全性、活性和免疫相关性。
N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.
10
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.在人类黑色素病变中，炎症反应与 B7-h1 表达的共定位支持了免疫逃避的适应性抵抗机制。
Sci Transl Med. 2012 Mar 28;4(127):127ra37. doi: 10.1126/scitranslmed.3003689.